Clinical Trial

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Name: A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer — clinical trial record (NCT07130916)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase 1, open-label, multicenter, multiple-dose study to evaluate aumolertinib in European participants with a confirmed diagnosis of activating EGFR mutation positive (EGFRm+) locally advanced or metastatic NSCLC.

Trial Details

NCT Number	NCT07130916
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	Non-Small Cell Lung Cancer
Enrollment	20 participants
Start Date	2024-12-05
Primary Completion	2025-08-09 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-19